Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE N/A. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $168M | $81M | $39M | $21M | $375M | $811M | $1.1B | — | — |
| Enterprise Value | $18M | $180M | $89M | $32M | $-22788710 | $306M | $744M | $1.0B | — | — |
| P/E Ratio → | -0.06 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 2.68 | 0.46 | 0.21 | 3.16 | 4.71 | 9.25 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -98.6% | -33.8% | -47.1% | -61.9% | -53.4% | -39.6% | -48.8% | — |
| ROA | -80.7% | -80.7% | -38.6% | -22.1% | -43.6% | -55.7% | -49.0% | -37.5% | -31.0% | -158.5% |
| ROIC | -485.6% | -485.6% | -73.5% | -38.6% | -73.3% | -86.9% | -69.6% | -53.0% | -69.7% | — |
| ROCE | -64.0% | -64.0% | -41.2% | -25.5% | -47.3% | -62.0% | -54.8% | -41.9% | -31.3% | -174.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.49 | 0.16 | 0.00 | 0.01 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 0.29 | -0.08 | -0.44 | -0.58 | -0.39 | -0.44 | -0.35 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -90.12 | — | — | — | -12.04 | -6.31 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.53 | 0.53 | 6.05 | 8.09 | 30.55 | 7.85 | 8.11 | 11.93 | 49.82 | 4.28 |
| Quick Ratio | 0.53 | 0.53 | 6.05 | 8.09 | 30.55 | 7.85 | 8.11 | 11.93 | 49.82 | 4.28 |
| Cash Ratio | 0.41 | 0.41 | 5.60 | 7.84 | 29.38 | 7.51 | 7.87 | 11.23 | 49.22 | 4.17 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $5M | $4M | $4M | $3M | $3M | $3M | $2M | $2M | $2M |
Critical liquidity and dilution
As reported in recent financial statements, QNCX has consistently generated negative ROIC, with figures reaching -80.6% in 2025Q3, reflecting the company's inability to deploy capital effectively across its shifting clinical pipeline while struggling to achieve any meaningful return on its historical investments in research and development.
The persistent negative ROIC suggests that the company's capital allocation has been value-destructive, as the firm continues to burn through resources without achieving clinical milestones that would justify the expenditure. Investors should monitor whether the pivot to the bone-targeting platform can eventually reverse this trend, though current data indicates a long path to positive capital efficiency.
Based on the 2026Q1 balance sheet, the company's current ratio of 2.92 appears deceptively stable, yet this metric masks a precarious cash position that, according to historical burn rates, leaves the firm highly vulnerable to clinical trial cost overruns and the urgent need for dilutive external financing.
While the current ratio suggests a degree of short-term coverage, the lack of revenue generation means that liquidity is entirely dependent on the remaining cash balance. Any delay in clinical progress or unexpected regulatory hurdles could rapidly exhaust these resources, leaving the company with limited options for survival outside of further equity dilution.
According to historical financial data, QNCX's debt-to-equity ratio has fluctuated wildly, peaking at 16.99 in 2025Q3, which indicates that the company's capital structure is heavily influenced by non-operational financing activities rather than a sustainable or predictable approach to managing long-term debt obligations or interest coverage.
The extreme volatility in leverage ratios suggests that the company's balance sheet is not managed for operational stability but rather for survival through intermittent capital raises. This lack of consistent leverage management warrants caution, as it implies that the firm's financial health is subject to the whims of capital markets rather than internal cash generation.
As indicated by the company's current financial profile, the use of P/E or EV/EBITDA ratios is fundamentally inappropriate for QNCX, as these metrics obscure the reality that the firm is a pre-revenue entity whose value is derived entirely from speculative clinical assets rather than current earnings.
Investors should instead focus on cash-burn-adjusted valuation metrics or the potential net present value of the bone-targeting platform's pipeline. Relying on traditional multiples in this context risks misinterpreting the company's financial distress as a valuation discount, when in reality, the metrics are simply not applicable to a business model that lacks commercial operations.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying QNCX stock.
Quince Therapeutics, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Based on historical data, Quince Therapeutics, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.